Information
15 Yonggu-daero 2469beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, South Korea
+82 31-260-9416
-
-
Overview
- Summary
- GC Green Cross MS, established as an independent corporation in 2003, originated from GC Green Cross's diagnostic business division in 1972. The company has led the development of the domestic in-vitro diagnostics sector for over 40 years. Its business encompasses the development, manufacturing, and sale of various healthcare products, including diagnostic reagents, diagnostic equipment, home medical devices, and hemodialysis solutions. The company's mission is to contribute to human health and aspire to be a global leader in the health industry.GC Green Cross MS, established as an independent corporation in 2003, originated from GC Green Cross's diagnostic business division in 1972. The company has led the development of the domestic in-vitro diagnostics sector for over 40 years. Its business encompasses the development, manufacturing, and sale of various healthcare products, including diagnostic reagents, diagnostic equipment, home medical devices, and hemodialysis solutions. The company's mission is to contribute to human health and aspire to be a global leader in the health industry.
- Key Products/Technologies
- Diagnostic Reagents: Development and supply of reagents for infectious diseases (such as HIV, HBV, HCV, influenza) and tumor markers, as well as parasitic disease testing. Capabilities in developing diagnostic reagents based on Real-Time molecular diagnostics and specific recombinant antibody generation technologies. A track record of launching Korea's first AIDS diagnostic reagent, 'GENEDIA HIV 1/2 ELISA'.Diagnostic Reagents: Development and supply of reagents for infectious diseases (such as HIV, HBV, HCV, influenza) and tumor markers, as well as parasitic disease testing. Capabilities in developing diagnostic reagents based on Real-Time molecular diagnostics and specific recombinant antibody generation technologies. A track record of launching Korea's first AIDS diagnostic reagent, 'GENEDIA HIV 1/2 ELISA'.
- Diagnostic Equipment: Domestic sales of 'Lumipulse Series' immunoassay analyzers (G600 II, G1200) from Fujirebio of Japan. These instruments offer fast and accurate testing for over 30 types of diseases, including hepatitis, AIDS, cancer, diabetes, thyroid disorders, and hormonal imbalances. The diagnostic method involves analyzing antigen-antibody reactions in patient blood samples.Diagnostic Equipment: Domestic sales of 'Lumipulse Series' immunoassay analyzers (G600 II, G1200) from Fujirebio of Japan. These instruments offer fast and accurate testing for over 30 types of diseases, including hepatitis, AIDS, cancer, diabetes, thyroid disorders, and hormonal imbalances. The diagnostic method involves analyzing antigen-antibody reactions in patient blood samples.
- Home Medical Devices (POCT): Blood glucose meters such as 'GC Fit Blood Glucose Meter (GGP-100)' and 'Gcare' blood glucose meters. High measurement accuracy and reliability achieved through red blood cell hematocrit correction function and improved glucose dehydrogenase-based measurement methods. Utilization of film-type strips for accurate measurement with small blood samples. Development and supply of 'Greencare A1c' glycated hemoglobin measurement system. The 'Greencare Lipid' cholesterol measurement system simultaneously checks four items—total cholesterol, HDL, LDL, and triglycerides—within 2 minutes and 30 seconds. Enhanced portability and user convenience with Bluetooth and Wi-Fi support.Home Medical Devices (POCT): Blood glucose meters such as 'GC Fit Blood Glucose Meter (GGP-100)' and 'Gcare' blood glucose meters. High measurement accuracy and reliability achieved through red blood cell hematocrit correction function and improved glucose dehydrogenase-based measurement methods. Utilization of film-type strips for accurate measurement with small blood samples. Development and supply of 'Greencare A1c' glycated hemoglobin measurement system. The 'Greencare Lipid' cholesterol measurement system simultaneously checks four items—total cholesterol, HDL, LDL, and triglycerides—within 2 minutes and 30 seconds. Enhanced portability and user convenience with Bluetooth and Wi-Fi support.
- Hemodialysis Solutions: Efforts to expand production capacity to meet increasing demand and secure domestic market share. This business segment represents a key diversification strategy for the company.Hemodialysis Solutions: Efforts to expand production capacity to meet increasing demand and secure domestic market share. This business segment represents a key diversification strategy for the company.
- Core Technologies: Multi-influenza diagnostic technology capable of detecting various influenza viruses (types A and B, H1N1, H3N2, etc.). Capabilities in developing core technologies required for POCT device development.Core Technologies: Multi-influenza diagnostic technology capable of detecting various influenza viruses (types A and B, H1N1, H3N2, etc.). Capabilities in developing core technologies required for POCT device development.
- Core Advantages
- Leading Position in Domestic In-Vitro Diagnostics: Over 40 years of experience in the diagnostic business, starting in 1972, establishing the company as a first-generation leader in the domestic in-vitro diagnostics sector. Experience in forming a marketing partnership with Germany's Boehringer Mannheim since 1978 and establishing a joint venture in 1992.Leading Position in Domestic In-Vitro Diagnostics: Over 40 years of experience in the diagnostic business, starting in 1972, establishing the company as a first-generation leader in the domestic in-vitro diagnostics sector. Experience in forming a marketing partnership with Germany's Boehringer Mannheim since 1978 and establishing a joint venture in 1992.
- Diversified Product Portfolio and Total Solution Provision: A broad range of products including diagnostic reagents, diagnostic equipment, home medical devices, and hemodialysis solutions. Capability to provide total solutions related to in-vitro diagnostics to hospitals and clinics.Diversified Product Portfolio and Total Solution Provision: A broad range of products including diagnostic reagents, diagnostic equipment, home medical devices, and hemodialysis solutions. Capability to provide total solutions related to in-vitro diagnostics to hospitals and clinics.
- Strengthened Global Market Expansion and Export Capabilities: A track record of exports to various countries across Asia, including the US, Russia, Africa, Latin America, and the Middle East. Focused efforts on the European market, leading to the acquisition of over 23 new international clients in countries like Romania and Serbia. Strategic partnership with Brazil's Fiocruz Foundation through an MOU for technology and R&D collaboration.Strengthened Global Market Expansion and Export Capabilities: A track record of exports to various countries across Asia, including the US, Russia, Africa, Latin America, and the Middle East. Focused efforts on the European market, leading to the acquisition of over 23 new international clients in countries like Romania and Serbia. Strategic partnership with Brazil's Fiocruz Foundation through an MOU for technology and R&D collaboration.
- Continuous R&D Investment and Technological Innovation: Commitment to market-oriented product development based on 'Open R&D/Innovation'. Development of Real-Time molecular diagnostic reagents and specific recombinant antibody generation technologies. Validation of technological competitiveness through the acquisition of a US patent for influenza diagnostic technology.Continuous R&D Investment and Technological Innovation: Commitment to market-oriented product development based on 'Open R&D/Innovation'. Development of Real-Time molecular diagnostic reagents and specific recombinant antibody generation technologies. Validation of technological competitiveness through the acquisition of a US patent for influenza diagnostic technology.
- Rigorous Quality and Safety Management: Attainment of CE-IVDR (In Vitro Diagnostic Regulation) certification from the European Union for key blood glucose and glycated hemoglobin products, affirming product quality and safety. Implementation of ESG management practices through international standard certifications such as ISO 14001 (Environmental Management System), ISO 45001 (Occupational Health and Safety Management System), and ISO 50001 (Energy Management System).Rigorous Quality and Safety Management: Attainment of CE-IVDR (In Vitro Diagnostic Regulation) certification from the European Union for key blood glucose and glycated hemoglobin products, affirming product quality and safety. Implementation of ESG management practices through international standard certifications such as ISO 14001 (Environmental Management System), ISO 45001 (Occupational Health and Safety Management System), and ISO 50001 (Energy Management System).
- Target Industrie
- Medical institutions (general hospitals, hospitals, clinics, etc.)Medical institutions (general hospitals, hospitals, clinics, etc.)
- Clinical laboratoriesClinical laboratories
- Home healthcare (for patients with chronic diseases such as diabetes and hyperlipidemia)Home healthcare (for patients with chronic diseases such as diabetes and hyperlipidemia)
- Public health (for infectious disease diagnosis and prevention)Public health (for infectious disease diagnosis and prevention)
- Major Markets
- Africa, AlgeriaAfrica, Algeria
- China, across AsiaChina, across Asia
- Poland, Switzerland, France, Romania, Serbia, Hungary, RussiaPoland, Switzerland, France, Romania, Serbia, Hungary, Russia
- USAUSA
- Latin America, BrazilLatin America, Brazil
- Certifications/Patents
- US patent acquisition for influenza virus detection technology (November 27, 2019).US patent acquisition for influenza virus detection technology (November 27, 2019).
- CE-IVDR (In Vitro Diagnostic Regulation) certification from the European Union (for blood glucose and glycated hemoglobin products).CE-IVDR (In Vitro Diagnostic Regulation) certification from the European Union (for blood glucose and glycated hemoglobin products).
- ISO 14001 (Environmental Management System) certification.ISO 14001 (Environmental Management System) certification.
- ISO 45001 (Occupational Health and Safety Management System) certification.ISO 45001 (Occupational Health and Safety Management System) certification.
- ISO 50001 (Energy Management System) certification.ISO 50001 (Energy Management System) certification.
Introduction
Location
15 Yonggu-daero 2469beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, South Korea
클릭하여 위치 살펴보기
